These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17353672)

  • 1. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
    Wierzbicki AS
    Curr Opin Lipidol; 2007 Apr; 18(2):227-9. PubMed ID: 17353672
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD; Cohen JC; Hobbs HH
    Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
    Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
    J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
    Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
    Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease variants, LDL, and coronary heart disease.
    Tall AR
    N Engl J Med; 2006 Mar; 354(12):1310-2. PubMed ID: 16554535
    [No Abstract]   [Full Text] [Related]  

  • 7. What promise does PCSK9 hold?
    Kastelein JJ; Fouchier SW; Defesche JC
    J Am Coll Cardiol; 2005 May; 45(10):1620-1. PubMed ID: 15893177
    [No Abstract]   [Full Text] [Related]  

  • 8. Beyond LDL cholesterol, a new role for PCSK9.
    Akram ON; Bernier A; Petrides F; Wong G; Lambert G
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence.
    Folsom AR; Peacock JM; Boerwinkle E
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2455-8. PubMed ID: 18006936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
    Piper DE; Jackson S; Liu Q; Romanow WG; Shetterly S; Thibault ST; Shan B; Walker NP
    Structure; 2007 May; 15(5):545-52. PubMed ID: 17502100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].
    Wu NQ; Li JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):444-446. PubMed ID: 28511335
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9　- Lessons From Recent Clinical Trials.
    Ishii H; Murohara T
    Circ J; 2017 Sep; 81(10):1386-1387. PubMed ID: 28579602
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives.
    Chan DC
    Atherosclerosis; 2011 Jul; 217(1):77-9. PubMed ID: 21444085
    [No Abstract]   [Full Text] [Related]  

  • 14. [PCSK9, from gene to protein: a new actor involved in cholesterol homeostasis].
    Abifadel M; Rabès JP; Boileau C; Varret M
    Med Sci (Paris); 2006 Nov; 22(11):916-8. PubMed ID: 17101087
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
    Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
    Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
    J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of novel mutations in the catalytic domain of the PCSK9 gene.
    Cameron J; Holla OL; Laerdahl JK; Kulseth MA; Ranheim T; Rognes T; Berge KE; Leren TP
    J Intern Med; 2008 Apr; 263(4):420-31. PubMed ID: 18266662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.
    Davignon J; Dubuc G; Seidah NG
    Curr Atheroscler Rep; 2010 Sep; 12(5):308-15. PubMed ID: 20623344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma PCSK9 levels correlate with cholesterol in men but not in women.
    Mayne J; Raymond A; Chaplin A; Cousins M; Kaefer N; Gyamera-Acheampong C; Seidah NG; Mbikay M; Chrétien M; Ooi TC
    Biochem Biophys Res Commun; 2007 Sep; 361(2):451-6. PubMed ID: 17645871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets and emerging therapies for reducing LDL cholesterol.
    Lilly SM; Rader DJ
    Curr Opin Lipidol; 2007 Dec; 18(6):650-5. PubMed ID: 17993811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.